SALT LAKE CITY--(BUSINESS WIRE)-- BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced that Grosshadern University Medical Center (Grosshadern), a premier medical center in Munich, Germany, celebrated 25 years of improving the outcome of cancer patients using hyperthermia.
During the celebration commemorating this significant milestone, the head of the Grosshadern hyperthermia unit, Prof. Rolf Issels, M.D., reported that the center has delivered 10,600 hyperthermia treatments. Dr. Issels stated, “The encouraging results of the first treatments of soft tissue sarcomas with hyperthermia and chemotherapy led to the Phase III trial that showed a clear benefit for adding hyperthermia to standard chemotherapy. We will continue our efforts to improve the outcome of cancer treatments using hyperthermia. Our next Phase III trial on the treatment of pancreatic cancer with hyperthermia combined with chemotherapy will start in the near future.”
Dr. Issels is a leading hyperthermia researcher who has been instrumental in the successful completion of a number of clinical studies that demonstrated the safety and effectiveness of the use of hyperthermia for the treatment of certain cancers.
The team of physicians, engineers and nursing staff, headed by Dr. Issels, started delivering hyperthermia using BSD's hyperthermia systems in 1986. Grosshadern currently has three BSD hyperthermia systems installed in the hyperthermia unit, including the first hyperthermia system combined with Magnetic Resonance (MR) imaging for non-invasive treatment monitoring.
About Grosshadern University Medical Center (Grosshadern)
Grosshadern is part of the University of Munich Medical Center. Munich Medical Center is the largest hospital complex in Munich, and has 45 clinics and hospitals with over 2,300 beds and 1,700 physicians. Grosshadern is a leading medical facility and has an international reputation for providing the highest standard in patient care.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for many years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia), while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.
BSD Medical Corporation
Dennis Gauger, 801-972-5555
KEYWORDS: United States Europe North America Germany Utah
INDUSTRY KEYWORDS: Health Biotechnology Hospitals Medical Devices Oncology